Aclaris Therapeutics (ACRS) EBT (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly EBT of -$37.5 million for Q1 2026, down 102.61% year-over-year from $1.4 billion in Q1 2025, and down 19.61% quarter-over-quarter from -$31.3 million in Q4 2025.
Aclaris Therapeutics (ACRS) EBT (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' EBT history runs 13 years deep, the most recent figure standing at -$37.5 million for Q1 2026.
- In Q1 2026, EBT fell 102.61% year-over-year to -$37.5 million; the TTM figure through Mar 2026 stood at -$106.8 million (up 27.77% YoY), while the FY2025 annual figure was -$273.0 million, down 106.7% from the prior year.
- EBT for Q1 2026 stood at -$37.5 million, down from -$31.3 million in the prior quarter.
- The five-year high for EBT was -$9.7 million in Q3 2024, with the low at -$197.0 million in Q4 2023.
- The 5-year median for EBT is -$32.9 million (2023), against an average of -$42.7 million.
- The sharpest annual moves came in 2023 and 2025: EBT slumped 349.74% in 2023, then surged 71.08% in 2025.
- Aclaris Therapeutics' EBT stood at -$43.8 million in 2022, then tumbled by 349.74% to -$197.0 million in 2023, then surged by 45.03% to -$108.3 million in 2024, then jumped by 71.08% to -$31.3 million in 2025, then declined by 19.61% to -$37.5 million in 2026.
- Business Quant data shows ACRS's EBT at -$37.5 million in Q1 2026, -$31.3 million in Q4 2025, and -$19.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -54.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.91 Mn |
| Mar 31, 2026 | -37.46 Mn |
| Dec 31, 2025 | -31.32 Mn |
| Sep 30, 2025 | -19.19 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Mar 31, 2025 | -18.49 Mn |
| Dec 31, 2024 | -108.29 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -11.47 Mn |
| Mar 31, 2024 | -17.43 Mn |
| Dec 31, 2023 | -196.98 Mn |
| Sep 30, 2023 | -32.94 Mn |
| Jun 30, 2023 | -39.00 Mn |
| Mar 31, 2023 | -34.12 Mn |
| Dec 31, 2022 | -43.80 Mn |
| Sep 30, 2022 | -36.39 Mn |
| Jun 30, 2022 | -32.17 Mn |
| Mar 31, 2022 | -38.01 Mn |
| Dec 31, 2021 | -36.83 Mn |
| Sep 30, 2021 | -38.44 Mn |